Page last updated: 2024-12-07

1-(3,4-methylenedioxyphenyl)-2-butanamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(3,4-methylenedioxyphenyl)-2-butanamine: RN given refers to cpd without isomeric designation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129870
CHEMBL ID61507
CHEBI ID190948
SCHEMBL ID987524
MeSH IDM0189917

Synonyms (30)

Synonym
BDB ,
CHEMBL61507
FT-0662551
1-(1,3-benzodioxol-5-yl)butan-2-amine
1-(1',3'-benzodioxol-5'-yl)-2-butanamine
CHEBI:190948
107447-03-0
1,3-benzodioxole-5-ethanamine, alpha-ethyl-
1-(3,4-methylenedioxyphenyl)-2-butanamine
unii-cm58wot28y
(3,4-methylenedioxyphenyl)-2-butanamine
alpha-ethyl-1,3-benzodioxole-5-ethanamine
1-mdpba
cm58wot28y ,
1,3-benzodioxolylbutanamine
AKOS009586096
2-amino-1-(3,4-methylenedioxyphenyl)-butane
VHMRXGAIDDCGDU-UHFFFAOYSA-N
SCHEMBL987524
3,4-methylenedioxy-alpha-ethylphenethylamine
.alpha.-ethyl-1,3-benzodioxole-5-ethanamine
1,3-benzodioxole-5-ethanamine, .alpha.-ethyl-
j (psychedelic)
3,4-methylenedioxybutanphenamine
1-(1,3-benzodioxol-5-yl)-2-butanamine
1-(2h-1,3-benzodioxol-5-yl)butan-2-amine
DTXSID30910325
( inverted exclamation marka)-1-(3,4-methylenedioxyphenyl)-2-butanamine hydrochloride 90
Q209303
bdb (hydrochloride)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodioxoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID191211Compound was tested for hallucinogenic activity in rats at 1.38 dose(mg/kg); Number of rats selecting the LSD lever/ number of rats responding (3/8)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID191400Compound was tested for hallucinogenic activity in rats at the dose 0.69(mg/kg); Number of rats selecting the LSD lever/ number of rats responding (0/8)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID91217Compound tested for hallucinogenic activity in humans was reported; Value reported in (A)= Mescaline units1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens.
AID191393Compound was tested for hallucinogenic activity in rats at the dose 0.34 (mg/kg); Number of rats selecting the LSD lever/ number of rats responding (0/8)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID191222Compound was tested for hallucinogenic activity in rats at 1.84 dose(mg/kg); 2/4, highest dose tested1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's4 (57.14)18.2507
2000's2 (28.57)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.45 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]